This is a pilot phase 2, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging, safety and efficacy study of oral AND017 to treat anemia in non-dialysis-dependent chronic kidney disease patients.
This is a pilot phase II study to evaluate the safety and efficacy of AND017 in NDD-CKD patients